The five-year CIR and EFS of STAP1 -high and STAP1 -low BCR-ABL1 -like and non- BCR-ABL1 -like B-other cases did not significantly differ in our cohort, although STAP1 -high cases showed a trend for a more favorable outcome (Fig. 6a,b ).
← all excerpts
High STAP1 expression in DUX4-rearranged cases is not suitable as therapeutic target in pediatric B-cell precursor acute lymphoblastic leukemia.
1
—
—